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I am a micronutrient researcher who has specialised in selenium (Se) since 2001. I 
believe Se should be a key component of treatment for Ebola patients. The correct use 
of Se in treatment for Ebola as recommended below is likely to reduce significantly 
the mortality rate and should be implemented as a matter of urgency. The current, 
supportive-based care is not good enough, as evidenced by the case fatality of over 
60%. Selenium must be included in order to give patients their best chance of 
recovery. 
 
 As an RNA virus, Ebola will be more active, and indeed will mutate to more virulent 
forms, in a Se-deficient host, e.g. a person with a plasma Se concentration less than 
around 75 micrograms/litre, a level common in Sub-Saharan Africa. As the disease 
progresses, in the absence of supplemented Se, the patient will become progressively 
more Se deficient, increasing oxidative stress/lipid peroxidation and compromising 





addition, Se plays a role in the regulation of blood clotting via its effects on the 
thromboxane/prostacyclin ratio, and effects on the complement system. Selenium has 
an anti-clotting effect, whereas Se deficiency has a pro-clotting or thrombotic effect. 
Proliferation of Ebola virus is likely to impose an unprecedented Se demand on the 
host, potentially leading to severe lipid peroxidation and cell membrane destruction, 
and contributing to haemorrhagic symptoms (Ramanathan & Taylor, 1997). People 
who are infected with the virus are more likely to recover if they can maintain an 
adequate Se status. 
 
A role for Se in Ebola treatment is also supported by the results of Chinese researchers, 
who treated patients in an outbreak of viral haemorrhagic fever with oral sodium 
selenite, obtaining dramatic reductions in mortality: after 9 days of Se dosage, the death 
rate fell from 100% (untreated) to 37% (treated) in the very severe cases, and from 22% 
to zero in the less severe cases (Hou, 1997) 
 
Suggested Se forms: sodium selenite or sodium selenate. 
 
Suggested dose (based on Hou et al 1997): 2 milligrams (i.e. 2000 micrograms) of 
selenate/selenite per day (which equates to 800 micrograms of actual Se). Preferably, 
administer the Se as a split dose, eg 400 micrograms in the morning and 400 mcg in the 
evening, otherwise one dose of 800 mcg/day. Take orally with a cup of water (it has no 
taste or smell). Intravenous administration is likely to be even more effective (use same 
dose). Starting with selenite/selenate powder and using successive dilutions it is easy 
to provide the required dose in 10-50 ml of water.  
 
Suggested duration: 10 days (followed by a maintenance dose of 0.25-0.5 of the above 
dose for a further 20 days). 
 
Safety: No adverse effects would be expected at this dose over this period, or indeed up 
to 30 days. Doctors in Melbourne dosed prostate cancer patients with over 15 
milligrams selenate per day for 2 months with minimal side-effects (Corcoran et al, 
2010) 
 
Cost: using a cost of A$200 for one kilogram of selenate or selenite (and I believe it 
can be bought cheaper than this if 50kg+ amounts are purchased, eg from the Lewer 
Corporation, Sydney), an amount which would provide enough Se for 500,000 daily 
doses at the above recommended rate, the cost of treating one person for 10 days is 
around half a cent, i.e. negligible. 
 
The main other treatment component which is likely to be effective against Ebola 
(especially when used in combination with Se) (Hou, 1997) is glycyrrhizin, a 
triterpenoid from licorice with liver protective and antiviral, anti-inflammatory and 
antidiabetic effects (Pu et al, 2013). Glycyrrhizin had a stronger benefit than the 
antiviral drug ribavirin in an animal study and was 30 times less toxic and 30 times less 
expensive (Utsunomiya et al, 1997). Its anti-inflammatory effect is related to its ability 





2008). The recommended antiviral dose: 600 mg/day, preferably IV as its 
bioavailability will be lower via oral. There appears to be synergism between 
glycyrrhizin and selenium: In a mouse model, combined selenite and glycyrrhizin 
inhibited immune complex-mediated tissue injury more effectively than either 
treatment alone (Hou, 1997). 
 
Selenium treatment (ideally together with glycyrrhizin) is urgently needed in the 
current Ebola epidemic. At the recommended dose it is safe, effective, inexpensive 
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